Int J Clin Exp Pathol 2016;9(12):13046
www.ijcep.com /ISSN:1936-2625/IJCEP0042486

Erratum
Bacterial extract OM-85 BV protects mice against experimental chronic rhinosinusitis: Int J Clin Exp Pathol. 2015; 8(6): 6800-6806

Yanli Tao[1,2], Tiejun Yuan[1], Xuechang Li[1], Shuqin Yang[1], Fanping Zhang[1], Li Shi[2]

[1]Department of Otolaryngology, Weifang People's Hospital, Weifang, P. R. China; [2]Department of Otolaryngology, Qilu Hospital of Shandong University, Jinan, P. R. China

Received October 21, 2016; Accepted October 27, 2016; Epub December 1, 2016; Published December 15, 2016

Abstract: Objectives: To investigate the therapeutic effects of OM-85 BV as an adjunctive treatment on experimental chronic rhinosinusitis (CRS) in mice. Methodology: Female BALB/c mice aged 8-12 weeks were sensitized and administrated by intranasal Aspergillus fumigatis (AF) three times per week for 1 week, 3 weeks, 2 months and 3 months (n = 10 each time point). The mice were randomly and equally assigned to four groups: normal control group, model group, OM-85-BV plus amoxicillin group, and isolated amoxicillin group. Inflammatory changes were determined by hematoxylin-eosin (HE) staining. The expression levels of suppressor of cytokine signaling (SOCS) 1, SOCS3, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ in samples were assessed by using real-time PCR (RT-PCR) and Western blotting. Results: There were significantly inflammatory and structural changes between the model and other groups. Compared to the model group, the mRNA expression levels of SOCS1, SOCS3, TNF-α, and IFN-γ were significantly decreased in OM-85-BV plus amoxicillin group and isolated amoxicillin group, along with the protein levels. Conclusion: The bacterial extract OM-85 BV is a low-cost alternatively adjunctive drug to treat CRS with simple oral administration, good safety, and few side effects.

Keywords: OM-85-BV, SOCS1, SOCS3, TNF-α, IFN-γ

In this article published in Int J Clin Exp Pathol, due to the recently new policy of hospital where the authors are working, the authors' name and information need to be corrected. The amended information as following:

Yanli Tao[1,2], Tiejun Yuan[2], Xuechang Li[2], Shuqin Yang[2], Fanping Zhang[2], Li Shi[1]

[1]Department of Otolaryngology, Qilu Hospital of Shandong University, Jinan, P. R. China; [2]Department of Otolaryngology, Weifang People's Hospital, Weifang, P. R. China

Address correspondence to: Dr. Li Shi, Department of Otolaryngology, Qilu Hospital of Shandong University, 107 Wenhua West Road, Jinan 250012, Shandong Province, P. R. China. Tel: +86-531-82169216; Fax: +86-531-87332617; E-mail: shili1549@126.com